One pill could change the fight against sleeping sickness in kids
NCT ID NCT05433350
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a single dose of the oral drug acoziborole in 35 children aged 1 to 14 with sleeping sickness (g-HAT). The goal was to see how the drug works in the body and if it is safe and effective. This simpler treatment could help control the disease in remote areas where access to care is limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLEEPING SICKNESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CDTC Katanda
Katanda, East Kasai, Democratic Republic of the Congo
-
General Hospital of Bandundu
Bandundu Province, Bandundu, Democratic Republic of the Congo
-
General Referral Hospital of Dubreka
Dubréka, Guinea
-
HGR Bagata
Bagata, Kwilu, Democratic Republic of the Congo
-
Hospital of Masi-Manimba
Masi-Manimba, Kwilu, Democratic Republic of the Congo
-
Hôpital Général de Dipumba
Mbuji-Mayi, East Kasai, Democratic Republic of the Congo
More trials for these conditions
Other studies related to the condition(s) this trial covers.